When Could Exparel See Generic Competition?
The entry date for generic competition for Exparel (bupivacaine liposome injectable emulsion) is currently uncertain, with factors like FDA ANDA status and patent litigation influencing market availability. While patents are in place, challenges and potential approvals for generic versions could alter the timeline.
What's the Status of ANDAs for Exparel Generics?
The U.S. Food and Drug Administration (FDA) reviews Abbreviated New Drug Applications (ANDAs) for generic drug approvals. The status of any submitted ANDAs for Exparel is not publicly detailed in the provided information, but their approval would be a prerequisite for generic market entry.
When Do Exparel's Patents Expire?
Exparel is protected by several patents. The core patent for Exparel is listed as U.S. Patent No. 8,071,144 [1]. However, the exact expiry dates and the status of any patent extensions or challenges directly impact when generic versions could legally enter the market. Information on specific patent expiry dates and ongoing litigation can be found through resources like DrugPatentWatch.com [2].
What Legal Challenges Could Affect Generic Entry?
Patent litigation is common in the pharmaceutical industry and can significantly delay or, in some cases, accelerate generic entry. If manufacturers of potential generic Exparel products are challenging existing patents, or if the patent holder is defending their intellectual property, these legal battles will directly influence the timeline for generic availability.
How Does Exparel Work?
Exparel is a long-acting local anesthetic [3]. It works by encapsulating bupivacaine in a multivesicular liposome, which allows for the slow release of the drug over time, providing pain relief for an extended period [3][4]. This mechanism of action is key to its therapeutic use in managing post-surgical pain [3].
What Are the Uses of Exparel?
Exparel is approved for various indications, including [3][4]:
* Management of post-surgical pain.
* Intercostal nerve block for brachial plexus block.
* Caudal block for patients 6 years of age and older.
* Adductor canal block.
* Local injection in the site of Bunions, hemorrhoids, and hernia repair.
Who Manufactures Exparel?
Exparel is manufactured by Pacira Pharmaceuticals, Inc. [4].